Verona Pharma PLC (VRNA)
13.00
-0.36
(-2.69%)
USD |
NASDAQ |
May 17, 16:00
13.03
+0.03
(+0.23%)
After-Hours: 20:00
Verona Pharma Enterprise Value: 847.73M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 847.73M |
| May 16, 2024 | 876.92M |
| May 15, 2024 | 924.76M |
| May 14, 2024 | 919.08M |
| May 13, 2024 | 919.08M |
| May 10, 2024 | 997.73M |
| May 09, 2024 | 989.62M |
| May 08, 2024 | 1.000B |
| May 07, 2024 | 992.86M |
| May 06, 2024 | 1.006B |
| May 03, 2024 | 1.066B |
| May 02, 2024 | 1.071B |
| May 01, 2024 | 1.025B |
| April 30, 2024 | 1.044B |
| April 29, 2024 | 1.053B |
| April 26, 2024 | 1.046B |
| April 25, 2024 | 1.033B |
| April 24, 2024 | 1.027B |
| April 23, 2024 | 1.055B |
| April 22, 2024 | 1.066B |
| April 19, 2024 | 1.066B |
| April 18, 2024 | 1.097B |
| April 17, 2024 | 1.121B |
| April 16, 2024 | 1.105B |
| April 15, 2024 | 1.072B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.081B |
| April 11, 2024 | 1.102B |
| April 10, 2024 | 1.110B |
| April 09, 2024 | 1.126B |
| April 08, 2024 | 1.160B |
| April 05, 2024 | 1.171B |
| April 04, 2024 | 1.132B |
| April 03, 2024 | 1.107B |
| April 02, 2024 | 1.083B |
| April 01, 2024 | 1.092B |
| March 28, 2024 | 1.023B |
| March 27, 2024 | 1.054B |
| March 26, 2024 | 1.027B |
| March 25, 2024 | 993.28M |
| March 22, 2024 | 1.021B |
| March 21, 2024 | 1.012B |
| March 20, 2024 | 1.010B |
| March 19, 2024 | 961.53M |
| March 18, 2024 | 979.34M |
| March 15, 2024 | 988.64M |
| March 14, 2024 | 980.12M |
| March 13, 2024 | 1.069B |
| March 12, 2024 | 1.108B |
| March 11, 2024 | 1.062B |
| March 08, 2024 | 1.088B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.37M
Minimum
Mar 18 2020
1.762B
Maximum
Dec 31 2022
488.27M
Average
233.77M
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals Plc | -2.388M |
| NuCana PLC | -14.39M |
| TC BioPharm (Holdings) PLC | 0.4733M |
| Bicycle Therapeutics PLC | 387.05M |
| Adaptimmune Therapeutics PLC | 140.02M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.79M |
| Total Expenses (Quarterly) | 26.61M |
| EPS Diluted (Quarterly) | -0.32 |
| Earnings Yield | -6.15% |
| Normalized Earnings Yield | -7.515 |